JEREMY HUNT: Open Payments
NPI 1144465600 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 42 payments from 11 companies in 2025. Trend: 2023 $716 · 2024 $516 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $126 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Braeburn Inc. | 1 | $26 |
| PFIZER INC. | 1 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Indivior Inc. | 1 | $22 |
| Novo Nordisk Inc | 1 | $20 |
| Exact Sciences Corporation | 1 | $19 |
Products named: VRAYLAR, CAPLYTA, Auvelity, BREZTRI, BRIXADI, PAXLOVID, ARISTADA, SUBLOCADE.
Industry payments across MD — which companies pay providers there.
